Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oxycodone HCl controlled-release Clear all
Terminated Phase 3 Interventional Results available

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

NCT02740114
View directory record Official record
Conditions
Malignant Neoplasms of Female Genital Organs, Gynecologic Cancer
Interventions
Bupivacaine, Liposomal Bupivacaine, Oxycodone, Pill Diary, Symptom Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2021 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

NCT00771758
View directory record Official record
Conditions
Back Pain
Interventions
oxycodone IR, placebo, tapentadol IR
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Haleyville, Alabama • Tallassee, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

NCT01369615
View directory record Official record
Conditions
Pain
Interventions
Oxycodone hydrochloride controlled-release tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
6 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Paramount, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2015 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

NCT01192295
View directory record Official record
Conditions
Pain
Interventions
Oxycodone HCl controlled-release tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
6 Years to 16 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 24, 2026, 3:53 AM EDT
Withdrawn Phase 4 Interventional

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

NCT01631513
View directory record Official record
Conditions
Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee
Interventions
Nucynta ER
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Jacksonville, Florida • Prairie Village, Kansas • Mandeville, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01427283
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
149
States / cities
Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study Investigating the nCAP Signal Relief Patch in Subjects Undergoing Primary Hip or Knee Replacement Surgery

NCT05252858
View directory record Official record
Conditions
Opioid Use, Pain, Post Operative
Interventions
nCAP Signal Relief Patch, Standard of Care
Device · Other
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 24, 2026, 3:53 AM EDT
Recruiting Phase 4 Interventional

Exparel and Education to Avoid Opioids After Carpal Tunnel Release

NCT03867539
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Differing pain management strategy
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 24, 2026, 3:53 AM EDT
Terminated Phase 2 Interventional

A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

NCT00483977
View directory record Official record
Conditions
Osteoarthritis
Interventions
Oxycodone, Placebo, PF-000592379
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
21
States / cities
Mobile, Alabama • Tucson, Arizona • Carmichael, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 4 Interventional Results available

Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors

NCT02351700
View directory record Official record
Conditions
Pituitary Tumor, Pain
Interventions
IV Caldolor, IV Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 79 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01358526
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone Controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
151
States / cities
Birmingham, Alabama • Haleyville, Alabama • Huntsville, Alabama + 123 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation

NCT01677039
View directory record Official record
Conditions
Healthy
Interventions
Test formulation administered with water, Test formulation administered with 20% ethanol, Test formulation administered with 40% ethanol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 24, 2026, 3:53 AM EDT
Recruiting Phase 3 Interventional

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

NCT03823534
View directory record Official record
Conditions
Bone Metastases, Lymphoma, Multiple Myeloma, Opioid Use, Pain
Interventions
Ketorolac, Normal saline, Acetaminophen, Oxycodone Acetaminophen, Morphine, Hydrocodone/Acetaminophen, Oxycodone
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 24, 2026, 3:53 AM EDT
Recruiting Phase 2 Interventional

NSAID Use After Robotic Partial Nephrectomy

NCT05842044
View directory record Official record
Conditions
Kidney Cancer, Renal Cancer, Renal Neoplasm
Interventions
Ketorolac, Acetaminophen, Oxycodone, Hydromorphone, Ibuprofen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 24, 2026, 3:53 AM EDT
Enrolling by invitation Phase 3 Interventional

Reduce Opiate Exposure With ACL Surgery

NCT06561035
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries
Interventions
Opiate Sparing, Opiate Based
Drug
Lead sponsor
Campbell Clinic
Other
Eligibility
14 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Skokie, Illinois • Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 24, 2026, 3:53 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis

NCT02452437
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Oxycodone
Drug
Lead sponsor
Emerio & Lourdes Linares Research and Education Center
Other
Eligibility
30 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 24, 2026, 3:53 AM EDT
Withdrawn Not applicable Interventional

Impact of the Number of Opiates Prescribed on Post Cesarean Pain Control

NCT03175653
View directory record Official record
Conditions
Post-operative Pain Control
Interventions
Oxycodone Pill A, Oxycodone Pill B
Other
Lead sponsor
Mount Carmel Health System
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

NCT02716857
View directory record Official record
Conditions
Moderate-to-severe Chronic Low Back Pain
Interventions
Oxycodone extended-release, Placebo of oxycodone extended-release
Drug
Lead sponsor
Egalet Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Satisfaction Following Cesarean Section

NCT03355248
View directory record Official record
Conditions
Pain, Postoperative, Cesarean Section Complications, Postpartum Disorder, Opioid Use
Interventions
Oxycodone Acetaminophen
Other
Lead sponsor
ProMedica Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Toward Zero Prescribed Opioids for Outpatient General Surgery

NCT05327777
View directory record Official record
Conditions
Opioid Misuse and Addiction, Pain
Interventions
Oxycodone, Zero Opioid Protocol
Drug · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 99 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

NCT01427270
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
170
States / cities
Alabaster, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Not applicable Interventional Results available

Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery

NCT01608308
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
IV Acetaminophen, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 68 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 24, 2026, 3:53 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Opioid Use After Laparoscopic Salpingectomy

NCT06434233
View directory record Official record
Conditions
Opioid Use, Post-operative Pain, Sterility, Female
Interventions
Acetaminophen, Ibuprofen, Oxycodone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 24, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain

NCT00463047
View directory record Official record
Conditions
Chronic Pain
Interventions
Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 24, 2026, 3:53 AM EDT